Introduction Interferon beta (IFN beta) preparations are an established group of drugs used
for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied …

Currently, there are four monoclonal antibodies (mAbs) that target the cluster of
differentiation (CD) 20 receptor available to treat multiple sclerosis (MS): rituximab …

The recent success of anti-CD20 monoclonal antibody therapies in the treatment of multiple
sclerosis (MS) has highlighted the role of B cells in the pathogenesis of MS. In people with …

Statistics such as the mean difference (MD), standardized mean difference (SMD), relative
risk (RR), odds ratio (OR), hazard ratio (HR), and others are meant to be examined along …

Multiple sclerosis (MS) is a clinically heterogenous disease. Currently, we cannot identify
patients with more active disease who may potentially benefit from earlier interventions …

Multiple sclerosis (MS) is a chronic, autoimmune, demyelinating disease of the central
nervous system (CNS). Microbes, including bacteria and certain viruses, particularly Epstein …

Objective: To describe a case of neoehrlichiosis, an emerging opportunistic tick-borne
infection, in a patient with multiple sclerosis (MS) treated with ocrelizumab. Methods: This is …

Autoimmune encephalitis (AE) broadly refers to inflammation of the brain parenchyma
mediated by autoimmune mechanisms. In most patients with AE, autoantibodies against …

B cells are critical to the pathogenesis of multiple sclerosis (MS), an autoimmune disease of
the central nervous system. B cell depletion using anti-CD20 monoclonal antibodies (mAbs) …

Background Babesiosis is a worldwide emerging protozoan infection that is associated with
a spectrum of disease severity from asymptomatic infection to severe organ damage and …